SUPN FY 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$409M+35.3% YoY

Gross Profit

$394M96.2% margin

Operating Income

$144M35.3% margin

Net Income

$111M27.1% margin

EPS (Diluted)

$2.05

Cash Flow

Operating Cash Flow

$129M

Free Cash Flow

$128M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$978M

Total Liabilities

$525M

Stockholders' Equity

$453M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$409M	$302M	+35.3%
Gross Profit	$394M	$287M	+37.1%
Operating Income	$144M	$100M	+45.1%
Net Income	$111M	$57M	+93.8%